Fernando Zanghelini

Dr. Fernando Zanghelini

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2024 in Geriatrics
Verified
Journal Article
Open access
PDF file
FZFernando Zanghelini
Fernando Zanghelini
APAisling Ponzo
Aisling Ponzo
GXGeorgios Xydopoulos
Georgios Xydopoulos
RFRichard Fordham
Richard Fordham
SKSaval Khanal
Saval Khanal
Background: GaitSmart (GS) is a sensor-based digital medical device that can be used with the integrated app vGym to provide a personalised rehabilitation programme for older people undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). This study aimed to determine whether the GS intervention used in the rehabilitation of older people undergoing THA or TKA is potentially cost-effective compared to the current standard of care (SoC). Methods: Decision-analytic modelling was conducted to estimate the cost-effectiveness over a seventeen-week time horizon from an NHS perspective. UK clinical and cost data from the GaitSmart randomised clinical trial was used to obtain the input parameters, and a sensitivity analysis was performed to address uncertainties. Results: Over a seventeen-week time horizon, GS incurred cost savings of GBP 450.56 and a 0.02 gain in quality-adjusted life years (QALYs) compared to the SoC. These results indicate that GS is the dominant intervention because the device demonstrated greater effectiveness and lower costs. Probabilistic sensitivity analyses confirm the robustness of our results. Conclusions: GS appears to offer short-term efficiency benefits and demonstrates cost-effectiveness for the improvement in gait in people undergoing THA or TKA, compared to the SoC.

18 January 2024 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
HCHenrique Lima Couto
Henrique Lima Couto
LGLudmila Peres Gargano
Ludmila Peres Gargano
VOVilmar Marques Oliveira
Vilmar Marques Oliveira
BCBertha Andrade Coelho
Bertha Andrade Coelho
EPEduardo Carvalho Pessoa
Eduardo Carvalho Pessoa
FZFernando Zanghelini
Fernando Zanghelini
Background Literature meta-analysis results show that digital breast tomosynthesis (DBT) combined with synthesized two-dimensional (s2D) mammograms can reduce recalls and improve breast cancer detection. Uncertainty regarding the screening of patients with breast cancer presents a health economic challenge, both in terms of healthcare resource use and quality of life impact on patients. Objective This study aims to estimate the cost effectiveness of DBT + s2D versus digital mammography (DM) used in a biennial breast cancer screening setting of women aged 40–69 years with scattered areas of fibroglandular breast density and heterogeneous dense breasts in the Brazilian supplementary health system. Methods A cost-effectiveness analysis was performed on the basis of clinical data obtained from a systematic review with meta-analysis performed to evaluate the analytical validity and clinical utility of DBT + s2D compared with DM. The search was conducted in the PubMed, Cochrane Library and Embase databases, with the main descriptors of the technology, a comparator, and the clinical condition in question, on 9 June 2022. The hybrid economic model (decision tree plus Markov model) simulated costs and outcomes over a lifetime for women aged 40–69 years with scattered areas of fibroglandular breast density and heterogeneous dense breasts. We analyzed incremental cost-effectiveness ratio (ICER) to measure the incremental cost difference per quality-adjusted life year (QALY) of adding DBT + s2D to breast cancer screening. Results DBT + s2D incurred a cost saving of € 954.02 per patient, in the time horizon of 30 years, compared with DM, and gained 5.1989 QALYs, which would be considered a dominant intervention. These results were confirmed in sensitivity analyses. Conclusion Switching from DM to biennial DBT + s2D was cost effective. Furthermore, reductions in false-positive recall rates should also be considered in decision making.

25 April 2025 in Rheumatology
Verified
Journal Article
Open access
FZFernando Zanghelini
Fernando Zanghelini
GXGeorgios Xydopoulos
Georgios Xydopoulos
SWSt Howard Wilsher
St Howard Wilsher
OAOyewumi Afolabi
Oyewumi Afolabi
DWDale Webb
Dale Webb
RFRichard Fordham
Richard Fordham
Objective: The objective of this study was to develop an economic model to determine the annual cost of delayed axial SpA diagnosis in the UK, adopting both National Health Service (NHS) and societal perspectives. Methods: We developed a Markov economic model to estimate the costs of delayed axial SpA diagnosis in the UK. Model parameters were sourced from a 2016 National Axial Spondyloarthritis Society patient survey, anonymized patient-level data, the published literature, and expert opinion. A literature-defined, mixed cohort (64% male) of people assumed to have axial SpA, whose age at symptom onset was 26 years, were targeted. To assess the robustness of the results, base case and probabilistic sensitivity analyses were performed. Results: In a simulated cohort of 1000 patients, with a mean time to diagnosis of 8.5 years, we estimate the cumulative costs of delayed diagnosis per person living with axial SpA to be £193 512 (95% CI: 108 770–306 789). The costs were led by productivity losses (65.1%) and out-of-pocket expenses (31.3%). The total annual cost resulting from delayed axial SpA diagnosis in the UK has been estimated at £3.1 billion and £12.5 billion, based on a prevalence of 0.3% (Assessment of SpondyloArthritis international Society classification criteria) and 1.2% (European Spondyloarthropathy Study Group classification criteria), respectively. Conclusion: Delayed axial SpA diagnosis carries high costs for society due to productivity losses. Early diagnosis and treatment could offer significant benefits to the patient and potentially reduce productivity losses; however, future research is needed to evaluate the long-term health economic impact.

1 February 2024 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
PDF file
TMToby M Maher
Toby M Maher
VTVeronica A Tudor
Veronica A Tudor
PSPeter Saunders
Peter Saunders
FZFernando Zanghelini
Fernando Zanghelini
CSCarlota Grossi Sampedro
Carlota Grossi Sampedro
PMPhilip L Molyneaux
Philip L Molyneaux
Background Interstitial lung disease frequently complicates systemic autoimmune disorders including scleroderma, idiopathic inflammatory myositis and mixed connective tissue disease, resulting in considerable morbidity and mortality. Based on the results of trials undertaken in scleroderma, cyclophosphamide is the standard of care for individuals with severe or progressive connective tissue disease-associated interstitial lung disease. Observational studies suggest that the anti-CD20 monoclonal antibody, rituximab is an effective rescue therapy in treatment of refractory connective tissue disease-associated interstitial lung disease, but it has not been studied as first-line therapy in clinical trials. Objectives To compare the safety and efficacy of rituximab against that of cyclophosphamide as treatment for individuals with severe, progressive interstitial lung disease associated with scleroderma, idiopathic inflammatory myositis or mixed connective tissue disease. Methods This was a Phase IIb, multicentre, randomised, double-blind, double-dummy study assessing the superiority of rituximab compared with cyclophosphamide, conducted in rheumatology or interstitial lung disease units at 11 UK centres. The study recruited individuals with extensive and/or progressive connective tissue disease-associated interstitial lung disease, excluding those with significant comorbidities, including airflow obstruction. Participants were randomised 1 : 1 to receive either rituximab 1 g given intravenously, twice at an interval of 2 weeks, or intravenous cyclophosphamide given monthly for 6 months at a dose of 600 mg/m2 body surface area. The primary end point for the study was the change in forced vital capacity at 24 weeks. Secondary end points included safety and tolerability, corticosteroid exposure, forced vital capacity change at 48 weeks and patient-reported quality of life. A cost-effectiveness analysis was undertaken to assess the impact of rituximab use in the United Kingdom National Health Service. Results One hundred and one subjects (70 females) with a mean age of 56.3 years were randomised; 51 to rituximab and 50 to cyclophosphamide. Ninety-seven were included in the modified intention-to-treat population for the primary and secondary efficacy analyses (49 in the rituximab group and 48 in the cyclophosphamide group). 38.6% had scleroderma, 44.6% idiopathic inflammatory myositis and 16.8% mixed connective tissue disease. Four subjects withdrew prior to the first dose of therapy (two in each arm). At 24 weeks, both rituximab and cyclophosphamide improved forced vital capacity from baseline [(mean ± standard deviation) 97 ± 234 and 99 ± 329 ml, respectively]. Using an adjusted mixed-effects model corrected for diagnosis and baseline forced vital capacity the difference in forced vital capacity at 24 weeks between rituximab and cyclophosphamide was −40 ml (95% CI −153 to 74 ml), p = 0.49. Other physiological and quality-of-life parameters improved in both arms following treatment but were not statistically significantly different between groups. Numerically fewer adverse events were reported by subjects receiving rituximab. Corticosteroid exposure over the 48 weeks of the trial was numerically less in the rituximab arm [13,291 (±14,657) mg of hydrocortisone equivalent per subject in the cyclophosphamide arm versus 11,469 (±10,041) mg per subject in the rituximab group; these differences did not reach statistical significance]. Limitations of the study include a disproportionate number of subjects being recruited from a single centre and insufficient subjects in each subgroup to determine whether there were treatment differences between individual connective tissue diseases. Based on the results of the trial, from a UK healthcare payer perspective, rituximab is more cost-effective than cyclophosphamide as a treatment for severe or progressive connective tissue disease-interstitial lung disease. Conclusions Rituximab improved forced vital capacity and patient-reported quality of life at 24 weeks but was not superior to cyclophosphamide. Rituximab should be considered as a therapeutic alternative to cyclophosphamide in individuals with connective tissue disease-associated interstitial lung disease requiring systemic therapy. Future work should explore the role of repeated dosing of rituximab and the use of rituximab earlier in the course of connective tissue disease-associated interstitial lung disease. Trial registration This trial is registered as ISRCTN16474148. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation Programme (NIHR award ref: 11/116/03) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 4. See the NIHR Funding and Awards website for further award information.

18 March 2026 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
RSRodrigo R. de Sena
Rodrigo R. de Sena
KMKleyton de C Mesquita
Kleyton de C Mesquita
LBLetícia F. Barroso
Letícia F. Barroso
PCPaola B. E. Canabrava
Paola B. E. Canabrava
FZFernando Zanghelini
Fernando Zanghelini
Ciro Martins GomesCiro Martins Gomes
Ciro Martins Gomes
Introduction Recent trials with withdrawal arms in patients with psoriasis have highlighted the need for updated clinical guidance. The aim of this investigation was to compare the effects and safety of planned limited-time withdrawal versus continuous maintenance of interleukin (IL) inhibitors in patients with psoriasis. Methods On August 5, 2025, the following platforms were systematically searched: PubMed, Embase, Clarivate (Web of Science), Scopus, and Ovid. Titles and abstracts, followed by full-text articles, were independently screened by two reviewers, with any disagreements being resolved by a third reviewer. Certainty of evidence was evaluated via the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Network meta-analyses for the Psoriasis Area and Severity Index (PASI) 90 and PASI100 outcomes were performed. The risk ratio (RR) of relapse was ranked using the surface under the cumulative ranking curve (SUCRA) metric. Results A total of 7444 records were retrieved, 54 of which included data from 18 different trials. The data revealed a total of 2995 patients who were subjected to anti-IL withdrawal regimens that were eligible for comparison with anti-IL maintenance. For the PASI90 outcome, the network meta-regression, adjusted for a post-withdrawal follow-up duration of 40–48 weeks, indicated that bimekizumab demonstrated a RR for relapse (RR 5.36; 95% confidence interval (CI) 3.45–8.34; SUCRA 0.685) comparable to that of guselkumab (RR 7.45; 95% CI 4.97–11.19; SUCRA 0.412) and lower than that of ixekizumab (RR 17.45; 95% CI 10.22–29.80; SUCRA 0.006). No significant difference in adverse event rates was observed between the anti-IL withdrawal and maintenance groups. Conclusions Compared with continued treatment, planned withdrawal of anti-IL therapy is associated with a largely superior risk of relapse, without any reduction in the incidence of adverse events. Moreover, bimekizumab withdrawal demonstrated better outcomes than ixekizumab withdrawal did according to the PASI90 outcome. Study Registration This study was prospectively registered on PROSPERO (identification number CRD420251118724).

20 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
FZFernando Zanghelini
Fernando Zanghelini
APAisling Ponzo
Aisling Ponzo
GXGeorgios Xydopoulos
Georgios Xydopoulos
RFRichard Fordham
Richard Fordham
SKSaval Khanal
Saval Khanal
Background: GaitSmart (GS) is a sensor-based digital medical device that can be used with the integrated app vGym to provide a personalised rehabilitation programme for older people undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). This study aimed to determine whether the GS intervention used in the rehabilitation of older people undergoing THA or TKA is potentially cost-effective compared to the current standard of care (SoC). Methods: Decision-analytic modelling was conducted to estimate cost-effectiveness over a seventeen- week time horizon, from an NHS perspective. UK clinical and cost data from the GaitSmart randomised clinical trial was used to obtain input parameters, and sensitivity analysis was performed to address uncertainty. Results: Over a seventeen-week time horizon, GS incurred cost savings of £450.56 and a 0.02 gain in quality-adjusted life years (QALYs) compared to the SoC. These results indicate that GS is the dominant intervention because the device demonstrated greater effectiveness and lower costs. Probabilistic sensitivity analyses confirm the robustness of our results. Conclusion: GS appears to offer short-term efficiency benefits and demonstrates cost-effectiveness for the improvement of gait in people undergoing THA or TKA, compared to the SoC. These findings provided new evidence to inform policymakers.